This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Colombia's move to cut cancer drug's price draws criticism

By Ira Teinowitz ( September 20, 2016, 22:00 GMT | Insight) -- A new move by Colombia to force a leading drugmaker to discount a cancer drug is quickly becoming a flash point in the long-running battle between those wanting more protection for US intellectual property and consumer groups wanting to make sure any new protections in trade deals don’t affect poor patients’ access to new life-saving medicines.A new move by Colombia to force a leading drugmaker to discount a cancer drug is quickly becoming a flash point in the long-running battle between those wanting more protection for US intellectual property and consumer groups wanting to make sure any new protections in trade deals don’t affect poor patients’ access to new life-saving medicines....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections